Table 1 Base-line characteristics of patients with FAP
Overall population | Group A: Celecoxib&UDCA | Group B: Celecoxib&Placebo | p value | |
|---|---|---|---|---|
Number of patients | 37 | 19 | 18 | |
Age at study entry, median/range (yr) | 42/22–67 | 42/22–67 | 41/27–64 | 0.9641 |
Sex (n, %) | 0.6182 | |||
Male | 18 (48.6) | 10 (52.6) | 8 (44.4) | |
Female | 19 (51.4) | 9 (47.4) | 10 (55.6) | |
Participants per centre (n, %) | 0.9323 | |||
RUNMC | 18 (48.6) | 10 (52.6) | 8 (44.4) | |
AMC | 10 (27.0) | 4 (21.1) | 6 (33.3) | |
EMC | 4 (10.8) | 2 (10.5) | 2 (11.1) | |
UMCG | 3 (8.1) | 2 (10.5) | 1 (5.6) | |
LUMC | 2 (5.4) | 1 (5.3) | 1 (5.6) | |
Body Mass Index, median/range (kg/m2) | 25.6/18.8–34.5 | 26.0/19.2–34.5 | 25.6/18.8–33.1 | 0.4081 |
Diagnosis FAP | 0.6603 | |||
Clinical only | 6 (16.2) | 4 (21.2) | 2 (11.1) | |
APC gene mutation | 31 (83.8) | 15 (78.9) | 16 (88.9) | |
Age at primary CR surgery, median/range (yr) | 21/7–60 | 22/7–60 | 18.5/11–48 | 0.2981 |
Time since primary CR surgery, median/range (yr) | 18/1–38 | 17/1–33 | 20.5/8–38 | 0.1781 |
Type of primary CR surgery | 0.7383 | |||
IRA | 18 (48.6)* | 10 (52.6)* | 8 (44.4) | |
IPAA | 14 (37.8) | 6 (31.6) | 8 (44.4) | |
Ileostomy | 5 (13.5) | 3 (15.8) | 2 (11.1) | |
Secondary CR surgery (n, %) | 11 (29.7) | 5 (26.3) | 6 (33.3) | 0.6412 |
Spigelman stage at last surveillance before entry | 0.9852 | |||
II | 19 (51.4)** | 10 (52.6) | 9 (50)** | |
III | 17 (45.9)** | 9 (47.4) | 8 (44.4)** |